Halma plc

LSE HLMA.L

Halma plc Price to Book Ratio (P/B) on January 14, 2025: 5.60

Halma plc Price to Book Ratio (P/B) is 5.60 on January 14, 2025, a 5.38% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.
  • Halma plc 52-week high Price to Book Ratio (P/B) is 6.16 on December 10, 2024, which is 10.01% above the current Price to Book Ratio (P/B).
  • Halma plc 52-week low Price to Book Ratio (P/B) is 4.66 on April 19, 2024, which is -16.67% below the current Price to Book Ratio (P/B).
  • Halma plc average Price to Book Ratio (P/B) for the last 52 weeks is 5.56.
Key data
Date Price to Book Ratio (P/B) Dividend Yield Free Cash Flow Yield Price to Earnings Ratio (P/E)
Market news
Loading...
LSE: HLMA.L

Halma plc

CEO Mr. Marc Arthur Ronchetti
IPO Date July 1, 1988
Location United Kingdom
Headquarters Misbourne Court
Employees 8,000
Sector Health Care
Industries
Description

Halma plc, through its subsidiaries, provides technology solutions in the safety, health, and environmental markets. It operates through three segments: Safety, Environmental & Analysis, and Medical. The Safety segment provides fire detection, specialist fire suppression, elevator safety, security sensors, people and vehicle flow technologies, specialized interlocks that control critical processes safely, and explosion protection and corrosion monitoring systems. This segment serves elevator safety, fire suppression, people and vehicle flow, fire detection, pressure management, industrial access control, and safe storage and transfer markets. The Environmental & Analysis segment offers optical, optoelectronic, and spectral imaging systems; water, air and gases monitoring technologies; instruments that detect hazardous gases and analyses air quality; and systems for water analysis and treatment. It serves the optical analysis, water analysis and treatment, gas detection, and environmental monitoring markets. The Medical segment provides critical fluidic components used by medical diagnostics and original equipment manufacturers; laboratory devices and systems that provide information to understand patient health and enable providers to make decisions across the continuum of care; technologies and solutions to enable in-vitro diagnostic systems and life-science discoveries and development; and technologies that enable positive outcomes across clinical specialties. This segment serves the life sciences, health assessment, and therapeutic solutions market. The company was incorporated in 1894 and is headquartered in Amersham, the United Kingdom.

Similar companies

CRDA.L

Croda International Plc

USD 38.05

-2.23%

ITRK.L

Intertek Group plc

USD 58.16

-0.66%

BNZL.L

Bunzl plc

USD 40.38

0.03%

SPX.L

Spirax-Sarco Engineering plc

USD 78.56

-0.22%

AHT.L

Ashtead Group plc

USD 61.33

3.34%

StockViz Staff

January 15, 2025

Any question? Send us an email